Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSK1349572 formulation AP · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part A | EXPERIMENTAL | Subjects will be randomized in a three-way crossover design to receive a single dose of each of three different tablet formulations of GSK1349572 50 mg (2 tablets). Formulation AP, AW and AX. |
| Part B | EXPERIMENTAL | A total of 18 subjects who complete Part A will return for Part B. Subjects from Part A will be asked to participate on a first come first served basis until there are 18 subjects, at which time enrolment to Part B will be closed. Part B will be a three way crossover design using either formulation AW or AX depending upon the results from Part A. Subjects will receive a single dose of 50 mg GSK1349572 with either a low fat, moderate fat or high fat meal in each period. |
| Name | Type | Description |
|---|---|---|
| GSK1349572 formulation AP | DRUG | GSK1349572 50 mg single dose fasted. |
| GSK1349572 formulation AW | DRUG | GSK1349572 formulation AW 50 mg single dose in Part A and 75 to 200 mg fasted or with moderate or high fat meal in Part B. |
| GSK1349572 formulation AX | DRUG | GSK1349572 formulation AX 50 mg in Part A and 75-200 mg fasted or with a moderate or high fat meal in Part B |
Inclusion Criteria: * AST, ALT, alkaline phosphatase and bilirubin less than or equla to 1.5xULN (isolated bilirubin \>1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%). * Healthy as determined by a responsible and experienced physician, based on a medical evaluation in...
GSK1349572 formulation AP is an investigational small molecule being studied for the treatment of Human Immunodeficiency Virus (HIV) infection. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
GSK1349572 formulation AP is being developed by GSK plc, a global biopharmaceutical company listed on the stock exchange under the ticker GSK. The company is conducting clinical trials to evaluate this investigational drug for HIV infection.
GSK1349572 formulation AP is in Phase 1 clinical development. It is an investigational drug and has not been approved for any use. The Phase 1 trial has been completed, and the drug remains under evaluation for the treatment of HIV infection.
GSK1349572 formulation AP has one completed clinical trial, NCT01098513, titled "GSK1349572 Relative Bioavailability Study." This Phase 1 study enrolled 24 participants in the United States, including healthy volunteers, and evaluated the drug's relative bioavailability.
GSK1349572 formulation AP is an investigational drug being developed by GSK plc for HIV infection. No alternative names have been disclosed for this specific formulation. It is currently in Phase 1 clinical development and has not been approved.